FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Reiterates Sell Opinion On Shares Of Martin Marietta Materials, Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by $39 to $531, valuing shares at an EV/EBITDA of 15.2x our next-12-month continuing operations EBITDA estimate, a discount to its five-year average of 16.1x. We justify our discount given our view of a less supportive construction environment compared to recent years that benefited from substantial IIJA funding. With the IIJA set to expire September 30, 2026, and no replacement currently in place, market expectations for sustained funding may not adequately reflect a scenario where infrastructure funding moves from delayed to canceled, in our opinion. We lower our 2026 EPS view by $0.47 to $19.45 and our 2027 EPS view by $1.37 to $23.10. MLM's focus on its core aggregates business drives our expectations for 180 bps of EBITDA margin expansion (cont. operations) to 35.4% as the divested lower-margin cement/ready-mix concrete operations no longer drag on consolidated margins, though elevated fuel costs and inflation-driven construction budget constraints may limit pricing power.

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL